技术评估：BL22，美国国立癌症研究所
Technology evaluation: BL22, NCI.
作者信息
Barth Stefan
机构信息
Institute of Biology, Aachen, Germany.
出版信息
Curr Opin Mol Ther. 2002 Feb;4(1):72-5.
PMID:11883697
Abstract
BL22 (RFB4(dsFv)-PE38) is a recombinant Pseudomonas exotoxin-based immunotoxin under development by the National Cancer Institute for the treatment of B-cell malignancies. It is composed of the disulfide-stabilized Fv portion of the anti-CD22 antibody RFB4 genetically fused to a truncated form of Pseudomonas exotoxin A. It has entered phase I trials for the treatment of B-cell lymphoma.
摘要
BL22（RFB4（dsFv）-PE38）是美国国立癌症研究所正在研发的一种基于重组绿脓杆菌外毒素的免疫毒素，用于治疗B细胞恶性肿瘤。它由抗CD22抗体RFB4的二硫键稳定Fv部分与绿脓杆菌外毒素A的截短形式基因融合而成。它已进入治疗B细胞淋巴瘤的I期试验。
Zotero 插件